Galapagos (GLPG) to Release Quarterly Earnings on Wednesday

Galapagos (NASDAQ:GLPG) is anticipated to post its Q4 2025 results before the market opens on Wednesday, February 11th. Analysts expect Galapagos to post earnings of $0.85 per share for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, February 24, 2026 at 7:00 AM ET.

Galapagos Stock Up 0.7%

Shares of Galapagos stock opened at $33.60 on Tuesday. The stock’s fifty day moving average is $32.99 and its 200 day moving average is $32.65. Galapagos has a one year low of $22.36 and a one year high of $37.78.

Hedge Funds Weigh In On Galapagos

Several institutional investors have recently bought and sold shares of GLPG. Jane Street Group LLC lifted its stake in Galapagos by 2,245.7% in the 1st quarter. Jane Street Group LLC now owns 110,783 shares of the biotechnology company’s stock worth $2,783,000 after purchasing an additional 115,946 shares in the last quarter. Geode Capital Management LLC bought a new stake in shares of Galapagos in the second quarter worth about $220,000. Jump Financial LLC purchased a new stake in shares of Galapagos in the second quarter worth about $692,000. Boothbay Fund Management LLC purchased a new stake in shares of Galapagos in the second quarter worth about $612,000. Finally, Engineers Gate Manager LP bought a new position in Galapagos during the second quarter valued at approximately $560,000. 32.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

GLPG has been the topic of several recent research reports. Wall Street Zen raised Galapagos from a “sell” rating to a “hold” rating in a research note on Tuesday, December 30th. Royal Bank Of Canada raised their target price on shares of Galapagos from $28.00 to $32.00 and gave the stock a “sector perform” rating in a research note on Friday, November 7th. Leerink Partners upgraded shares of Galapagos from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 22nd. Weiss Ratings reissued a “sell (d)” rating on shares of Galapagos in a research note on Thursday, January 22nd. Finally, Sanford C. Bernstein assumed coverage on shares of Galapagos in a research note on Wednesday, November 26th. They set a “hold” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus price target of $31.33.

Galapagos Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.